Genetic testing for TP53 is recommended by the National Comprehensive Cancer Network (NCCN, http://www.nccn.org) in accordance with the Chompret criteria, or in any breast cancer patient < 30 years of age testing negative test for BRCA1 and BRCA2 mutations. This evidence concerns the gene BRCA2 and breast cancer.